Key Points
- CEO August Troendle sold 8,770 Medpace shares at an average price of $621.29, generating approximately $5.45 million; his remaining stake totaled 515,153 shares.
- Medpace reported quarterly EPS of $4.25, beating estimates of $3.98, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
- Analysts maintain a consensus “Hold” rating with an average price target of $595.20, despite some upgrades and target increases; institutional investors own nearly 78% of the stock.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 8,770 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $621.29, for a total transaction of $5,448,713.30. Following the transaction, the chief executive officer owned 515,153 shares of the company's stock, valued at approximately $320,059,407.37. The trade was a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Medpace Stock Performance
Shares of MEDP stock opened at $615.18 on Friday. The firm has a market cap of $17.17 billion, a price-to-earnings ratio of 36.06, a P/E/G ratio of 2.75 and a beta of 1.15. The firm's 50-day simple moving average is $584.38 and its two-hundred day simple moving average is $509.80. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analysts' expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.
Institutional Trading of Medpace
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Medpace during the 2nd quarter valued at $1,323,047,000. Wasatch Advisors LP raised its position in shares of Medpace by 19.4% in the first quarter. Wasatch Advisors LP now owns 773,931 shares of the company's stock worth $371,634,000 after buying an additional 125,625 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after buying an additional 24,625 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Medpace by 8.3% during the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company's stock valued at $242,337,000 after buying an additional 38,760 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Medpace by 5.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company's stock valued at $190,044,000 after buying an additional 20,736 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
MEDP has been the topic of several recent research reports. Jefferies Financial Group restated a "hold" rating on shares of Medpace in a research report on Monday. Leerink Partners set a $620.00 price target on Medpace in a research report on Thursday, July 23rd. Mizuho boosted their price objective on Medpace from $586.00 to $665.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. Robert W. Baird increased their price objective on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a report on Friday, July 24th. Finally, Weiss Ratings upgraded Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 12th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $595.20.
Read Our Latest Research Report on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.
Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
